KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Construction in Progress: 2012-2018

Historic Construction in Progress for Alnylam Pharmaceuticals (ALNY) over the last 6 years, with Dec 2018 value amounting to $261.0 million.

  • Alnylam Pharmaceuticals' Construction in Progress rose 95.27% to $261.0 million in Q4 2018 from the same period last year, while for Dec 2018 it was $261.0 million, marking a year-over-year increase of 95.27%. This contributed to the annual value of $261.0 million for FY2018, which is 95.27% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Construction in Progress of $261.0 million as of FY2018, which was up 95.27% from $133.6 million recorded in FY2017.
  • In the past 5 years, Alnylam Pharmaceuticals' Construction in Progress ranged from a high of $261.0 million in FY2018 and a low of $1.3 million during FY2015.
  • Moreover, its 2-year median value for Construction in Progress was $197.3 million (2017), whereas its average is $197.3 million.
  • Its Construction in Progress has fluctuated over the past 5 years, first skyrocketed by 6,978.57% in 2014, then crashed by 35.17% in 2015.
  • Alnylam Pharmaceuticals' Construction in Progress (Yearly) stood at $2.0 million in 2014, then tumbled by 35.17% to $1.3 million in 2015, then reached $133.6 million in 2017, then spiked by 95.27% to $261.0 million in 2018.